# Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

> **NCT01123304** · PHASE1 · TERMINATED · sponsor: **Morphotek** · enrollment: 18 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** MORAb028

## Key facts

- **NCT ID:** NCT01123304
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** This study has been terminated due to lack of availability of investigational product.
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123304, "Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01123304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*